Collagen Matrix Acquires Polyganics

Collagen Matrix Acquires Polyganics

The Investment Expands CMI’s Regenerative Medicine Portfolio, R&D Capabilities and International Manufacturing Operations Oakland, N.J., October 5, 2022 – Collagen Matrix, Inc. (“Collagen Matrix”), a global leader in regenerative medicine and a Linden Capital Partners (“Linden”) portfolio company, today announced the acquisition of Polyganics, B.V (“Polyganics”).  Polyganics is a medical technology company that develops and…

Read More

Collagen Matrix, Inc. Selected to Participate in FDA’s Experiential Learning Program

Collagen Matrix, Inc. Selected to Participate in FDA’s Experiential Learning Program Collagen Matrix, Inc., a leading provider of high quality products and technology used in tissue repair and regeneration announced today it has been selected to participate in the Food and Drug Administration’s Experiential Learning Program (ELP).  The ELP is designed to provide the FDA’s…

Read More

Collagen Matrix, Inc. Completes Transaction with Metalmark Capital

Collagen Matrix, Inc. Completes Transaction with Metalmark Capital Collagen Matrix, Inc., a leading provider of high quality products and technology used in tissue repair and regeneration, today announced the completion of a majority investment by Metalmark Capital, a New York-based private equity firm. Metalmark’s investment in Collagen Matrix will provide the resources, expertise and capital…

Read More

Collagen Matrix, Inc. Receives FDA 510(k) Clearance of a Flexible Collagen Nerve Conduit for Reduction of Painful Neuroma Formation

Collagen Matrix, Inc. Receives FDA 510(k) Clearance of a Flexible Collagen Nerve Conduit for Reduction of Painful Neuroma Formation Collagen Matrix, Inc. announced today that it has received FDA’s 510(k) clearance of its Flexible Collagen Nerve Conduit for management of peripheral nerve injuries at nerve ends in the foot to reduce the formation of painful…

Read More